Company update: DSM Q2 2011
DSM reports strong Q2 results with solid growth. Q2 EBITDA from continuing operations was €339 million, which was higher than in both Q2 2010 and Q1 2011.
The strong Life Sciences results were driven by a robust growth in Nutrition, and very solid results in Materials Sciences due to pricing strength and volume growth.
DSM reports that the Martek integration on track and showed an excellent Q2 EBITDA performance. Furthermore EPS more than doubled, reflecting strong operating results, lower tax rate and one-off gains.
2011 is expected to be a strong year with good progress towards achieving the 2013 targets.
Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: "Whilst general economic forecasts for the year continue to be positive, there are increased uncertainties related to the global economy.
“However, we believe we are well positioned with our balanced, relatively resilient portfolio in health, nutrition and materials, and with our broad geographic footprint, strong technology and leading market positions.
“This, in combination with our focus on customers and innovation and our ongoing efficiency improvements, gives us confidence that 2011 will be a strong year for DSM with good progress towards achieving the 2013 targets."
For a more detailed DSM Q2 report read this press release (pdf).
